Literature DB >> 8856448

Age and breed differences in thyroid hormones, insulin-like growth factor (IGF)-I and IGF binding proteins in female horses.

K Malinowski1, R A Christensen, H D Hafs, C G Scanes.   

Abstract

A survey with horses was conducted to determine whether plasma concentrations of triiodothyronine (T3), thyroxine (T4), insulin-like growth factor (IGF)-I and IGF binding proteins (IGFBP) change as horses grow, mature sexually, and age. Jugular blood was sampled from Standardbred fillies and mares at ages 0, 1, 7, and 14 d, at 1, 2, 4, 5, 6, and 9 mo, and at 5 to 8 and 16 to 22 yr (n = 5 to 18). In a second survey, we measured the same variables in eight breeds of horses with markedly different adult body sizes, from Miniatures to Friesians. Plasma T3, T4, and IGF-I were determined by radioimmunoassays validated for horses, and IGFBP were estimated from radioligand assay following separation of the IGFBP by SDS-PAGE electrophoresis. Plasma T3 decreased (P < .01) nearly continuously from 7.9 ng/mL on the day of birth to .9 ng/mL at 6 mo, and then changed little from .7 ng/mL at 9 mo to .5 ng/mL in mares 16 to 22 yr old. Similarly, T4 declined (P < .01) from 233 ng/mL on the day of birth to 49 ng/mL at 14 d and varied from 35 to 9 ng/mL among all of the older age groups. Plasma concentrations of IGF-I increased (P < .01) from 285 ng/mL on the day of birth to 572 ng/mL at 14 d, remained relatively constant until 9 mo of age (530 ng/mL), and then declined (P < .01) to low levels (295 ng/mL) in the oldest mares. We detected six IGFBP. The two smallest IGFBP (26 and 39 kDa) were highest during the first 14 d after birth and lowest (P < .01) in aged mares. The four larger IGFBP were lowest at birth and increased to the highest values during the most rapid growth period, but these changes were not significant (P > .20). In agreement with data for other species, our data suggest that IGF-I and IGFBP modulate growth in horses. Although there were impressive interbreed differences in circulating concentrations of T3, T4, IGF-I, and IGFBP, these were not related to differences in adult body size.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856448     DOI: 10.2527/1996.7481936x

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  5 in total

1.  Plasma concentration of insulin-like growth factor I (IGF-I) in growing Ardenner horses suffering from juvenile digital degenerative osteoarthropathy.

Authors:  J-Ph Lejeune; T Franck; M Gangl; N Schneider; C Michaux; G Deby-Dupont; D Serteyn
Journal:  Vet Res Commun       Date:  2007-01-09       Impact factor: 2.459

2.  The concentration of iodine in horse serum and its relationship with thyroxin concentration by geological difference.

Authors:  Mariko Mochizuki; Noriyuki Hayakawa; Fumiko Minowa; Akihiro Saito; Katsumi Ishioka; Fukiko Ueda; Kimihiro Okubo; Hiroyuki Tazaki
Journal:  Environ Monit Assess       Date:  2016-03-14       Impact factor: 2.513

3.  Variations of plasmatic concentrations of Insulin-like Growth Factor-I in post-pubescent horses affected with developmental osteochondral lesions.

Authors:  D R Verwilghen; L Vanderheyden; T Franck; V Busoni; E Enzerink; M Gangl; J-P Lejeune; G van Galen; S Grulke; D Serteyn
Journal:  Vet Res Commun       Date:  2009-03-25       Impact factor: 2.459

4.  Enhanced or reduced fetal growth induced by embryo transfer into smaller or larger breeds alters post-natal growth and metabolism in pre-weaning horses.

Authors:  Pauline Peugnet; Laurence Wimel; Guy Duchamp; Charlotte Sandersen; Sylvaine Camous; Daniel Guillaume; Michèle Dahirel; Cédric Dubois; Luc Jouneau; Fabrice Reigner; Valérie Berthelot; Stéphane Chaffaux; Anne Tarrade; Didier Serteyn; Pascale Chavatte-Palmer
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

5.  Maternal obesity increases insulin resistance, low-grade inflammation and osteochondrosis lesions in foals and yearlings until 18 months of age.

Authors:  M Robles; E Nouveau; C Gautier; L Mendoza; C Dubois; M Dahirel; B Lagofun; M-C Aubrière; J-P Lejeune; I Caudron; I Guenon; C Viguié; L Wimel; H Bouraima-Lelong; D Serteyn; A Couturier-Tarrade; P Chavatte-Palmer
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.